Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GIANT: Gemcitabine/Nab-Paclitaxel vs 5-FU/Leucovorin/Liposomal Irinotecan in Older Patients With Metastatic Pancreatic Cancer
NCT04233866Phase 2Active, not recruiting
- Sponsor
- ECOG-ACRIN Cancer Research Group
- Start
- Aug 2020
- Primary completion
- Mar 2026
- Modality
- Lipid-based Nanoparticles, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in pancreatic adenocarcinoma (PDAC) comparing Arm A (gemcitabine, nab-paclitaxel) with Arm B (fluorouracil, leucovorin, liposomal irinotecan) (2 arms). Primary endpoint: Overall Survival. Started Aug 2020; status: active, not recruiting.
02
Drugs
gemcitabinepaclitaxelfluorouracilfolinic acidnanoliposomal irinotecan
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT04233866.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04233866.